Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier

Chirality

Volumn 15, Issue 7, 2003, Pages 593-599

  Bergeron, Raymond J ^a,d   Wiegand, Jan ^a   Weimar, William R ^a,c   McManis, James S ^a   Smith, Richard E ^a   Abboud, Khalil A ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Florida   (United States)

^c SOUTHERN UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cebus apella; Iron clearance; Plasma concentration time curve; X ray crystallography

Indexed keywords

4' HYDROXYDESAZADESFERRITHIOCIN; CREMOPHOR; DEFEROXAMINE; DEFERRIFERRITHIOCIN; IRON; IRON CHELATING AGENT; IRON DEXTRAN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CEBIDAE; CELL MEMBRANE TRANSPORT; CIRCULAR DICHROISM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; ENANTIOMER; FECES ANALYSIS; IRON CHELATION; IRON OVERLOAD; LEUKEMIA L 1210; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOICHIOMETRY; URINALYSIS; URINARY EXCRETION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CEBUS; CRYSTALLOGRAPHY, X-RAY; DIHYDROPYRIDINES; FECES; HUMANS; IRON CHELATING AGENTS; MICE; STEREOISOMERISM; THIAZOLES;

EID: 0041663758     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10248     Document Type: Article

References (47)

1. Raymond KN, Carrano CJ. Coordination chemistry and microbial iron transport. Acc Chem Res 1979;12:183-190.
2. Tufano TP, Raymond KN. Coordination chemistry of microbial iron transport compounds. 21. Kinetics and metabolism of iron exchange in hydroxamate siderophore complexes. J Am Chem Soc 1981;103:6617-6624.
3. Neilands JB. Some aspects of microbial iron metabolism. Bacteriol Rev 1957;21:101-111.
4. Neilands JB. Siderophores: structure and function of microbial iron transport compounds. J Biol Chem 1995;270:26723-26726.
5. Byers BR, Arceneaux JE. Microbial iron transport: iron acquisition by pathogenic microorganisms. Met Ions Biol Syst 1998;35:37-66.
6. Leong SA, Winkelmann G. Molecular biology of iron transport in fungi. Met Ions Biol Syst 1998;35:147-186.
7. Bergeron RJ, McManis JS. Synthesis of catecholamide and hydroxamate siderophores. In: Winkelmann G, editor. CRC handbook of microbial iron chelates. Boca Raton, FL: CRC; 1991. p 271-307.
8. Bergeron RJ, Kline SJ. Short synthesis of parabactin. J Am Chem Soc 1982;104:4489-4492.
9. Bergeron RJ, McManis JS, Dionis JB, Garlich JR. An efficient total synthesis of agrobactin and its gallium(III) chelate. J Org Chem 1985;50:2780-2782.
10. Mulqueen GC, Pattenden G, Whiting DA. Synthesis of the thiazoline-based siderophore (S)-desferrithiocin. Tetrahedron 1993;49:5359-5364.
11. Bergeron RJ, Wiegand J, Weimar WR, Vinson JRT, Bussenius J, Yao GW, McManis JS. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. J Med Chem 1999;42:95-108.
12. Bergeron RJ, McManis JS, Wiegand J, Weimar WR. A search for clinically effective iron chelators. In: Badman DG, Bergeron RJ, Brittenham GM, editors. Iron chelators: new development strategies. Ponte Vedra Beach, FL: Saratoga; 2000. p 253-292.
13. Hahn FE, McMurry TJ, Hugi A, Raymond KN. Coordination chemistry of microbial iron transport. 42. Structural and spectroscopic characterization of diastereomeric Cr(III) and Co(III) complexes of desferriferrithiocin. J Am Chem Soc 1990;112:1854-1860.
14. Anderegg G, Räber M. Metal complex formation of a new siderophore desferiithiocin and of three related ligands. J Chem Soc Chem Commun 1990:1194-1196.
15. Bergeron RJ, Dionis JB, Elliott GT, Kline SJ. Mechanism and stereospecificity of the parabactin-mediated iron-transport system in Paracoccus denitrificans. J Biol Chem 1985;260:7936-7944.
16. Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol Aspects Med 2001;22:1-87.
17. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998;35:35-54.
18. Theil EC, Huynh BH. Ferritin mineralization: ferroxidation and beyond. J Inorg Biochem 1997;67:30.
19. Ponka P. Physiology and pathophysiology of iron metabolism: implications for iron chelation therapy in iron overload. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC; 1994. p 1-29.
20. Babbs CF. Oxygen radicals in ulcerative colitis. Free Radic Biol Med 1992;13:169-181.
21. Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994;52:253-265.
22. Hazen SL, d'Avignon A, Anderson MM, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to oxidize α-amino acids to a family of reactive aldehydes. Mechanistic studies identifying labile intermediates along the reaction pathway. J Biol Chem 1998;273:4997-5005.
23. Halliwell B. Iron, oxidative damage, and chelating agents. In: Bergeron RJ, Brittenham GM, editors. The development of iron chelators for clinical use. Boca Raton, FL: CRC; 1994. p 33-56.
24. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
25. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin Hematol 2001;38:360-366.
26. Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 1986;36:466-472.
27. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Bailliere's Clin Haematol 1989;2:323-343.
28. Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem 1999;42:2432-2440.
29. Bergeron RJ, Streiff RR, Creary EA, Daniels RD Jr, King W, Luchetta G, Wiegand J, Moerker T, Peter HH. A comparative study of the ironclearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 1993;81:2166-2173.
30. Sheldrick GM. SHELXTL5 Madison, WI: Bruker-AXS; 2000.
31. Farrugia LJ. ORTEP-3 for Windows (v. 1.06). Glasgow; 2000.
32. Bergeron RJ, Streiff RR, Wiegand J, Luchetta G, Creary EA, Peter HH. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992;79:1882-1890.
33. Wood JK, Milner PF, Pathak UN. The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol 1968;14:119-129.
34. Bergeron RJ, Streiff RR, Wiegand J, Vinson JRT, Luchetta G, Evans KM, Peter H, Jenny H-B. A comparative evaluation of iron clearance models. Ann NY Acad Sci 1990;612:378-393.
35. Bergeron RJ, Wiegand J, Brittenham GM. HBED: A potential alternative to deferoxamine for iron-chelating therapy. Blood 1998;91:1446-1452.
36. Bergeron RJ, Wiegand J, Wollenweber M, McManis JS, Algee SE, Ratliff-Thompson K. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators. J Med Chem 1996;39:1575-1581.
37. Bergeron RJ, Wiegand J, Brittenham GM. HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 1999;93:370-375.
38. Bergeron RJ, Wiegand J, Ratliff-Thompson K, Weimar WR. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin: Iron-clearing properties. Ann NY Acad Sci 1998;850:202-216.
39. Bergeron RJ, Weimar WR, Wiegand J. Pharmacokinetics of orally administered desferrithiocin analogs in Cebus apella primates. Drug Metab Dispos 1999;27:1496-1498.
40. 11-diethylnorspermine. Drug Metab Dispos 1995;23:1117-1125.
41. 14-diethylhomospermine. Drug Metab Dispos 1996;24:334-343.
42. Bergeron RJ, Müller R, Bussenius J, McManis JS, Merriman RL, Smith RE, Yao H, Weimar WR. Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives. J Med Chem 2000;43:224-235.
43. Zhao F, Liang Y, Zhang Y, Tong S. Study on the structure and properties of 4-(2-pyridylazo)resorcinol (PAR) and its derivatives. Chin Chem Lett 1992;3:107-108.
44. Drozdzewski PM. Resonance raman spectra of tautomeric forms of 1-(2-pyridylazo)-2-naphthol and 4-(2-pyridylazo)resorcinol. Spectrochim Acta A: Mol Biomol Spectrosc 1985;41A:1035-1039.
45. Rastetter WH, Erickson TJ, Venuti MC. Synthesis of iron chelators. Enterobactin, enantioenterobactin, and a chiral analogue. J Org Chem 1981;46:3579-3590.
46. Bergeron RJ, Cavanaugh PF Jr, Kline SJ, Hughes RG Jr, Elliott GT, Porter CW. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. Biochem Biophys Res Commun 1984;121:848-854.
47. Bergeron RJ. Iron: a controlling nutrient in proliferative processes. Trends Biochem Sci 1986;11:133-136.